Adding Pembrolizumab To Preoperative Radiotherapy and Surgery Improves DFS for Patients with Stage III Soft Tissue Sarcomas of the Extremity By Ogkologos - December 2, 2024 874 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SU2C-SARC032 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Latest episode of our podcast for researchers May 23, 2022 Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer March 11, 2019 Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC... September 23, 2025 Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma May 23, 2023 Load more HOT NEWS FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... Workout Wednesday – Back Stretches Part 2 What to Know About Peer-Reviewed Cancer Information and Its Role in... Breathing for Stress Reduction
